ClinicalTrials.gg
CompletedNCT02573467Updated Mar 13, 2018Results posted

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

A Phase 3 interventional study of Bimagrumab and Placebo in Sporadic Inclusion Body Myositis, sponsored by Novartis Pharmaceuticals. Completed at 38 sites in 10 countries. Open to participants aged 36 Years and older. Per ClinicalTrials.gov, last updated 2018-03-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
211
Allocation
Non-randomized
Ages
36 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Myositis, Inclusion Body with a site in United States — 4 open to participants now, 9 under way, 2 of them phase 3. Myositis, Inclusion Body · United States.

Enrollment
4th of 27
211 · median 24
Started
2015
the only one that year
Phase 3
3 of 37
none open now
Registered
20th of 37
by date
Lead sponsor
6 of 37
Novartis Pharmaceuticals

Among the 37 studies in Myositis, Inclusion Body with a site in United States, this one is the 4th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 3, and was the 20th registered.

Myositis, Inclusion Body

65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.

Browse Myositis, Inclusion Body studies →

Open to participants now

4 of the 37 studies in Myositis, Inclusion Body with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Myositis, Inclusion Body studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 36 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Myositis, Inclusion Body with a site in United States, or all of them as a file.
02

Study summary

This extension study will provide data to further evaluate the efficacy, safety, and tolerability of three doses of BYM338 and to assess the long-term effects of BYM338 in patients with sporadic inclusion body myositis. The extension study was planned to consist of a Screening epoch (to assess patient eligibility), followed by a Treatment Period 1 epoch (double-blind and placebo-controlled), and a Treatment Period 2 epoch (open-label). A Post-treatment Follow-up (FUP) epoch was also planned for patients who discontinued prematurely. Patients who complete the core study and qualify for this extension study entered Treatment Period 1 and continued on the study drug to which they were randomized in the core study (either to one of the three bimagrumab doses (1 mg/kg, 3 mg/kg, and 10mg/kg) or placebo) during Treatment Period 1. Thus, Treatment Period 1 was double-blind and placebo-controlled. Participants were to continue in Treatment Period 1 until the dose with the best benefit-risk profile was determined from the core study data and selected (duration of Treatment Period 1 was estimated to be between 6 and 8 months). Once the dose with the best benefit-risk profile was selected, all participants (including those who were receiving placebo) were planned to enter Treatment Period 2 and switch to open-label treatment with bimagrumab at the selected dose. The core study has been completed but since the core study did not meet the primary end point (no bimagrumab dose was identified based on the core study efficacy results) the extension study was terminated as per protocol/sponsor's decision; therefore, no patients had entered Treatment Period 2. Instead, all patients were to return for the End of Treatment Period 1 (EOT1) visit at their next scheduled visit. As per protocol, all patients who discontinued study medication during Treatment Period 1 for any reason, including due to the study having been stopped as per protocol/sponsor's decision, were to have entered and complete the 6-month FUP after their EOT1 visit.

Due to the nature of the design of the core and extension studies and termination of study medication in the extension study, the treatment duration for individual patients varied considerably. Consequently, the number of patients contributing data to the efficacy analyses at Week 104 and later timepoints was decreased.

03

Conditions studied

  • Sporadic Inclusion Body Myositis

Keywords

  • sporadic inclusion body myositis,
  • muscle wasting,
  • extension study,
  • BYM338,
  • bimagrumab,
04

Who can participate

Ages eligible
36 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed the core study
  • Written must be obtained before any extension study assessment is performed.
  • Able to communicate well with the investigator.
  • Willing to participate for the entire duration of the extension study with commitment to follow study requirements and procedures.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant
  • Women of unless they are using highly effective methods of during dosing and for 6 months after the last BYM338 dose.
  • Current use of prohibited treatments
  • History of severe reaction in the core study
  • History of adverse event(s) (including those from the core study) prior to the start of study drug in the extension study that, in the judgment of the investigator, taking into account the subject's overall status, prevent the subject from entering the extension study
  • abnormal liver function tests
  • Any medical condition or laboratory finding which, in the opinion of the investigator may interfere with participation in the study, might confound the results of the study, or pose an additional safety risk in administering BYM338
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    BYM338/bimagrumab 10 mg/kg

    Participants received BYM338 10 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.

    Drug: Bimagrumab

  • Experimental
    BYM338/bimagrumab 3 mg/kg

    Participants received BYM338 3 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.

    Drug: Bimagrumab

  • Experimental
    BYM338/bimagrumab 1 mg/kg

    Participants received BYM338 1 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.

    Drug: Bimagrumab

  • Placebo comparator
    Placebo

    Participants received placebo administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.

    Drug: Placebo

Interventions

  • BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.

    Also known as: BYM338

  • DrugPlacebo

    Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths.

    Safety monitoring was conducted throughout the study. AEs starting on or after the day of first administration of extension study drug until last administration of study drug + 56 days are considered. SAEs starting on or after the day of first administration of extension study drug are considered. Deaths which occurred on or after the day of first administration of extension study drug are considered.

    Time frame: to end of study (up to 14 months, including the 6-month treatment-free follow-up period)

  2. Change From Core Study Baseline in 6 Minute Walking Distance Test (6MWD)

    The 6MWD test measures the distance (in meters) that a participant can walk in a 6 minute time frame. A positive change from baseline indicates improvement. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.

    Time frame: Core study baseline, weeks 52, 78, 104, and >=117

Secondary outcomes

  1. Change From Core Study Baseline in Quadriceps Quantitative Muscle Testing (QMT) on the Right Side

    Quantitative Muscle Testing (QMT) was used to describe the long-term evolution of quadriceps muscle strength on the right side. The QMT was performed using the same portable fixed dynamometry (PFD) used in the core study. A negative change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.

    Time frame: Core study baseline, week 52, week 78, week 104 and >=week 117

  2. Change From Core Study Baseline in Sporadic Inclusion Body Myositis (sIBM) Functional Assessment (sIFA) Score

    Self-reported physical function was assessed by a newly developed patient reported outcome named sporadic inclusion body myositis (sIBM) functional assessment (sIFA). The sIFA consists of 11 items scored on an 11 point numerical rating scale from 0 (no difficulty) to 10 (unable to do) across 3 domains: upper body functioning, lower body functioning and general functioning. Participants completed the assessment where the recall period was the past week prior to completing the patient reported outcome (PRO). The total score on the sIFA scale ranges from 0 (minimum) to 110 (maximum). Higher values represent a worse outcome. A positive change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.

    Time frame: Core study baseline, week 52, week 78, week 104, and >=week 117

  3. Estimated Annual Number of Falls Per Participant Within Treatment Group

    Participants documented any fall occurrences in a paper diary during the study.

    Time frame: Core baseline to end of extension double-blind treatment (up to a maximum of 32 months)

  4. Change From Core Study Baseline in Short Physical Performance Battery (SPPB) Score

    The SPPB evaluated lower extremities function by testing gait speed, ability to keep standing balance and time to rise from a chair five times. The sub-score for each test ranged from 0 to 4. The summary score, which was a summation of scores from the 3 tests, ranged from 0 to 12. An increase in score indicates improvement in physical performance. A negative change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.

    Time frame: Core study baseline, week 52, week 78, week 104 and >=week 117

  5. Change in Muscles of the Thigh

    Magnetic resonance imaging (MRI) was planned to be used to characterize changes in muscles of the thigh in a subset of patients.

    Time frame: up to 1 year, up to 2 years

  6. Number of Patients With Anti-BYM338 Antibodies

    Investigated the development of immunogenicity against BYM338.

    Time frame: end of double-blind treatment (up to 8 months)

07

Results

Posted Mar 13, 2018

Participant flow

Participants entered extension study treatment period after completing the core study and continued on the study drug to which they were randomized in the core study (one of 3 bimagrumab doses (1mg/kg, 3mg/kg or 10mg/kg) or placebo). Participants discontinued from the treatment period were to enter a 6-month, treatment-free Follow-up Period (FUP).

Double-blind Treatment Epoch
Participant flow — Double-blind Treatment Epoch
MilestoneBYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlacebo
Started53525155
Full analysis set53525155
Completed0000
Not completed53525155
Withdrew: Lack of efficacy0010
Withdrew: Adverse event1010
Withdrew: Withdrawal by subject2110
Withdrew: Study terminated by sponsor50514855
Post-treatment Follow up Epoch
Participant flow — Post-treatment Follow up Epoch
MilestoneBYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlacebo
Started41464447
Completed35413444
Not completed65103
Withdrew: Death1101
Withdrew: Withdrawal by subject5492
Withdrew: Technical problems0010

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths.

Safety monitoring was conducted throughout the study. AEs starting on or after the day of first administration of extension study drug until last administration of study drug + 56 days are considered. SAEs starting on or after the day of first administration of extension study drug are considered. Deaths which occurred on or after the day of first administration of extension study drug are considered.

Time frame:
to end of study (up to 14 months, including the 6-month treatment-free follow-up period)
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths.
ParticipantsBYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlacebo
Adverse events48504449
Serious adverse events121078
Deaths1112
PrimaryChange From Core Study Baseline in 6 Minute Walking Distance Test (6MWD)

The 6MWD test measures the distance (in meters) that a participant can walk in a 6 minute time frame. A positive change from baseline indicates improvement. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.

Time frame:
Core study baseline, weeks 52, 78, 104, and >=117
Reported as:
Mean · meters
Change From Core Study Baseline in 6 Minute Walking Distance Test (6MWD)
metersBYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlacebo
Week 52 (n=53,52,51,54)6.88 ± 68.9489.48 ± 81.676-14.26 ± 81.029-5.98 ± 78.817
Week 78-5.25 ± 122.002-9.73 ± 68.302-18.66 ± 81.536-32.78 ± 96.494
Week 104-22.68 ± 102.549-50.58 ± 118.012-25.08 ± 95.737-61.30 ± 107.399
>=Week 117-206.65 ± 281.923-5.0 ± NA-53.65 ± 114.32231.60 ± NA
SecondaryChange From Core Study Baseline in Quadriceps Quantitative Muscle Testing (QMT) on the Right Side

Quantitative Muscle Testing (QMT) was used to describe the long-term evolution of quadriceps muscle strength on the right side. The QMT was performed using the same portable fixed dynamometry (PFD) used in the core study. A negative change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.

Time frame:
Core study baseline, week 52, week 78, week 104 and >=week 117
Reported as:
Mean · newtons
Change From Core Study Baseline in Quadriceps Quantitative Muscle Testing (QMT) on the Right Side
newtonsBYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlacebo
Week 52-6.29 ± 31.121-19.70 ± 77.820-5.62 ± 32.245-14.22 ± 27.577
Week 78-9.43 ± 41.285-23.76 ± 73.729-17.04 ± 25.696-21.02 ± 31.391
Week 104-11.92 ± 35.243-16.99 ± 34.379-18.63 ± 37.968-21.91 ± 39.985
>=Week 11767.64 ± NA33.38 ± NA-19.36 ± 18.475-18.24 ± NA
SecondaryChange From Core Study Baseline in Sporadic Inclusion Body Myositis (sIBM) Functional Assessment (sIFA) Score

Self-reported physical function was assessed by a newly developed patient reported outcome named sporadic inclusion body myositis (sIBM) functional assessment (sIFA). The sIFA consists of 11 items scored on an 11 point numerical rating scale from 0 (no difficulty) to 10 (unable to do) across 3 domains: upper body functioning, lower body functioning and general functioning. Participants completed the assessment where the recall period was the past week prior to completing the patient reported outcome (PRO). The total score on the sIFA scale ranges from 0 (minimum) to 110 (maximum). Higher values represent a worse outcome. A positive change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.

Time frame:
Core study baseline, week 52, week 78, week 104, and >=week 117
Reported as:
Mean · score on a scale
Change From Core Study Baseline in Sporadic Inclusion Body Myositis (sIBM) Functional Assessment (sIFA) Score
score on a scaleBYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlacebo
Week 52-1.34 ± 15.2491.80 ± 11.9103.17 ± 11.3805.16 ± 13.889
Week 78-0.27 ± 13.7455.33 ± 13.0996.52 ± 12.9187.41 ± 14.410
Week 1043.54 ± 14.9988.04 ± 16.8615.97 ± 12.8497.39 ± 15.580
>=Week 117-16.37 ± 21.85710.91 ± NA1.37 ± 17.6556.36 ± NA
SecondaryEstimated Annual Number of Falls Per Participant Within Treatment Group

Participants documented any fall occurrences in a paper diary during the study.

Time frame:
Core baseline to end of extension double-blind treatment (up to a maximum of 32 months)
Reported as:
Number · Annual number of falls per participant
Estimated Annual Number of Falls Per Participant Within Treatment Group
Annual number of falls per participantBYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlacebo
Estimated Annual Number of Falls Per Participant Within Treatment Group4.1643.8793.4803.835
SecondaryChange From Core Study Baseline in Short Physical Performance Battery (SPPB) Score

The SPPB evaluated lower extremities function by testing gait speed, ability to keep standing balance and time to rise from a chair five times. The sub-score for each test ranged from 0 to 4. The summary score, which was a summation of scores from the 3 tests, ranged from 0 to 12. An increase in score indicates improvement in physical performance. A negative change from baseline indicates deterioration. The efficacy analysis and time points were based on windowed visits relative to the first dose of the double-blind treatment in the core study.

Time frame:
Core study baseline, week 52, week 78, week 104 and >=week 117
Reported as:
Mean · score on a scale
Change From Core Study Baseline in Short Physical Performance Battery (SPPB) Score
score on a scaleBYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlacebo
Week 520.3 ± 1.730.2 ± 1.61-0.4 ± 1.74-0.3 ± 1.31
Week 78-0.5 ± 2.58-0.1 ± 1.54-0.4 ± 1.69-0.9 ± 1.92
Week 104-1.4 ± 3.29-0.9 ± 2.77-1.1 ± 2.56-1.3 ± 2.35
>=Week 117-3.0 ± 4.240.0 ± NA0.3 ± 2.060.0 ± NA
SecondaryChange in Muscles of the Thigh

Magnetic resonance imaging (MRI) was planned to be used to characterize changes in muscles of the thigh in a subset of patients.

Time frame:
up to 1 year, up to 2 years

No measurements were reported for this outcome.

SecondaryNumber of Patients With Anti-BYM338 Antibodies

Investigated the development of immunogenicity against BYM338.

Time frame:
end of double-blind treatment (up to 8 months)
Reported as:
Number · Participants
Number of Patients With Anti-BYM338 Antibodies
ParticipantsBYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlacebo
Number of Patients With Anti-BYM338 Antibodies0102

Adverse events

Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit, up to 14 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BYM338/Bimagrumab 10 mg/kg1/53 (1.9%)12/53 (22.6%)40/53 (75.5%)
BYM338/Bimagrumab 3 mg/kg1/52 (1.9%)10/52 (19.2%)46/52 (88.5%)
BYM338/Bimagrumab 1 mg/kg1/51 (2%)7/51 (13.7%)38/51 (74.5%)
Placebo2/55 (3.6%)8/55 (14.5%)43/55 (78.2%)
Pooled Active Treatment Groups3/156 (1.9%)29/156 (18.6%)124/156 (79.5%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventBYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlaceboPooled Active Treatment Groups
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/530/522/511/553/156
SepsisInfections and infestations1/530/520/512/551/156
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/530/521/512/551/156
PneumoniaInfections and infestations1/531/521/511/553/156
UrosepsisInfections and infestations0/530/521/510/551/156
Avulsion fractureInjury, poisoning and procedural complications0/530/521/510/551/156
FallInjury, poisoning and procedural complications0/530/521/511/551/156
Peripheral arterial occlusive diseaseVascular disorders0/530/521/510/551/156
Peripheral venous diseaseVascular disorders0/530/521/510/551/156
Oesophageal achalasiaGastrointestinal disorders0/531/520/510/551/156
Most frequent other events
Showing 10 of 31
Most frequent other events
EventBYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlaceboPooled Active Treatment Groups
FallInjury, poisoning and procedural complications30/5336/5230/5134/5596/156
ContusionInjury, poisoning and procedural complications9/537/5212/518/5528/156
DiarrhoeaGastrointestinal disorders9/535/529/515/5523/156
Muscle spasmsMusculoskeletal and connective tissue disorders4/538/523/511/5515/156
LacerationInjury, poisoning and procedural complications1/537/524/516/5512/156
Skin abrasionInjury, poisoning and procedural complications6/537/524/515/5517/156
ArthralgiaMusculoskeletal and connective tissue disorders1/535/526/516/5512/156
Pain in extremityMusculoskeletal and connective tissue disorders1/535/523/512/559/156
Ligament sprainInjury, poisoning and procedural complications5/532/522/513/559/156
HypertensionVascular disorders5/532/522/511/559/156

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlaceboTotal
Mean69.2 ± 8.1967.3 ± 9.0470.0 ± 7.6969.9 ± 7.9569.1 ± 8.24
Sex: Female, Male
Sex: Female, Male(Participants)BYM338/Bimagrumab 10 mg/kgBYM338/Bimagrumab 3 mg/kgBYM338/Bimagrumab 1 mg/kgPlaceboTotal
Female1819171973
Male35333436138
08

Study locations

38 sites
  • Novartis Investigative Site
    Phoenix, Arizona 85028, United States
  • Novartis Investigative Site
    Orange, California 92868, United States
  • Novartis Investigative Site
    Sacramento, California 95817, United States
  • Novartis Investigative Site
    Miami, Florida 33101, United States
  • Novartis Investigative Site
    Kansas City, Kansas 66160, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21287, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02114, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02115, United States
  • Novartis Investigative Site
    Columbus, Ohio 43221, United States
  • Novartis Investigative Site
    Portland, Oregon 97239, United States
  • Novartis Investigative Site
    Dallas, Texas 75235, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    St. Leonards, New South Wales 2065, Australia
  • Novartis Investigative Site
    Cauldfield, Victoria 3162, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Edegem, Antwerpen 2650, Belgium
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Copenhagen, 2100, Denmark
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    Roma, Lazio 00168, Italy
  • Novartis Investigative Site
    Messina, ME 98125, Italy
  • Novartis Investigative Site
    Milano, MI 20133, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Nagoya, Aichi 466-8560, Japan
  • Novartis Investigative Site
    Kumamoto City, Kumamoto 860-8556, Japan
  • Novartis Investigative Site
    Sendai-city, Miyagi 980-8574, Japan
  • Novartis Investigative Site
    Osaka-city, Osaka 534-0021, Japan
  • Novartis Investigative Site
    Kodaira, Tokyo 187-8551, Japan
  • Novartis Investigative Site
    Wakayama-city, Wakayama 641-8510, Japan
  • Novartis Investigative Site
    Tokushima, 770-8503, Japan
  • Novartis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • Novartis Investigative Site
    Leiden, 2333 ZA, Netherlands
  • Novartis Investigative Site
    Zuerich, 8091, Switzerland
  • Novartis Investigative Site
    Salford, Manchester M6 8HD, United Kingdom
  • Novartis Investigative Site
    London, NW1 2BU, United Kingdom
  • Novartis Investigative Site
    Newcastle upon Tyne, NE4 5PL, United Kingdom
09

References and documents

Publications

  • Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tanko LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021 Mar 23;96(12):e1595-e1607. doi: 10.1212/WNL.0000000000011626. Epub 2021 Feb 17. PubMed 33597289 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Aug 2016, 9 months.

Results were first posted in Mar 2018, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2015
First posted
Oct 9, 2015
StartActual
Nov 2, 2015
Primary completionActual
Aug 17, 2016
CompletionActual
Feb 13, 2017
Results first posted
Mar 13, 2018
Last update
Mar 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02573467
Responsible party
Sponsor
First posted
Oct 9, 2015
Start date
Nov 2, 2015
Primary completion
Aug 17, 2016
Completion
Feb 13, 2017
Results posted
Mar 13, 2018
Last update
Mar 13, 2018

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimagrumab

Start the discussion